kff glp-1 KFF's survey of Medicaid officials found 16 state Medicaid programs covered GLP-1s for obesity treatment as of October 2025. Since then, four states (CA, NH, PA, SC) have ended coverage and NC High Price of Popular Diabetes

Verpakking Complete Research Kit met zorgvuldig samengestelde steriele laboratoriumbenodigdheden

However, despite these results, Novo Nordisks shares declined post-announcement, as investors had anticipated even stronger outcomes, particularly in the T2D cohort, where the efficacy lagged behind emerging triple agonists like retatrutide

More progress on the weight-loss treatment front: A lot of pharmaceutical companies, particularly Novo Nordisk [which makes Ozempic and Wegovy] and Eli Lilly [which makes Zepbound], have been studying and reformulating oral weight-loss meds to improve how well theyre absorbed by the body, continues Corrado

We emphasize the importance of compassionate care and support throughout the treatment process